Rapporto sull’analisi delle dimensioni del mercato e dell’analisi delle quote degli inalatori respiratori | Previsioni 2031

  • Report Code : TIPRE00003093
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 254
Buy Now

Si prevede che il mercato degli inalatori respiratori crescerà da 31.144,56 milioni di dollari nel 2022 a 43.446,19 milioni di dollari entro il 2028; si stima che registrerà un CAGR del 5,7% dal 2022 al 2028.

Gli inalatori respiratori vengono utilizzati per inalare farmaci che sono una parte essenziale del trattamento delle malattie polmonari croniche. Sono usati sia per prevenire che per curare le esacerbazioni di queste malattie croniche. Offrono il vantaggio di evitare l’esposizione sistemica ai farmaci garantendo al tempo stesso che i farmaci raggiungano direttamente i polmoni. Numerosi prodotti rilasciano farmaci direttamente nelle vie aeree, come inalatori a polvere secca, inalatori predosati (MDI), nebulizzatori e inalatori a nebbia leggera. Si prevede che il mercato degli inalatori respiratori crescerà a causa della crescente prevalenza di malattie respiratorie come asma, broncopneumopatia cronica ostruttiva (BPCO), fibrosi cistica, sindrome da sovrapposizione asma-BPCO e altre.

Approfondimenti strategici 

Approfondimenti sul mercato degli inalatori respiratori

La crescente adozione di inalatori generici guida la crescita del mercato degli inalatori respiratori

I farmaci per inalazione che coinvolgono un'ampia gamma di dispositivi inalatori rappresentano il pilastro dell'attività farmacologica trattamento dell’asma e della BPCO. I pazienti affetti da asma e BPCO spesso necessitano di uno o più inalatori al giorno per mantenere sane le vie respiratorie. Pertanto, gli operatori sanitari sono preoccupati per il passaggio da un farmaco all’altro poiché ciò può avere un impatto negativo sul controllo della malattia a causa della scarsa aderenza e dell’uso improprio dei tipi di dispositivi di erogazione dell’aerosol. Con la crescente pressione sui bilanci sanitari e la contemporanea scadenza dei brevetti sui trattamenti inalatori consolidati, diversi prodotti sostitutivi generici vengono fabbricati e forniti in tutto il mondo. Diversi inalanti utilizzati per trattare l’asma includono formulazioni generiche, come albuterolo, levalbuterolo, ipratropio, budesonide e fluticasone/salmeterolo. Gli inalatori generici sono bioequivalenti alle versioni di marca e hanno lo stesso effetto sull'organismo. Il numero di inalatori generici per l’asma continua ad aumentare con la scadenza dei brevetti. Il 3 marzo 2020, la Food and Drug Administration (FDA) ha autorizzato gli inalatori generici per l'asma e la polvere generica di corticosteroidi inalatori. Nell'aprile 2020, la FDA ha approvato un inalatore generico, a base di albuterolo solfato, per soddisfare le esigenze dei pazienti affetti da COVID-19 con difficoltà respiratorie. Poiché sul mercato entrano sempre più farmaci generici, è prevista una maggiore concorrenza che, a sua volta, porta a una riduzione dei costi dei farmaci. La riduzione dei costi può anche derivare dal lancio di un "farmaco generico approvato". Pertanto, la crescente adozione di inalatori generici e farmaci per l'asma sta migliorando l'aderenza ai farmaci, guidando così il mercato degli inalatori respiratori.

Approfondimenti basati sul tipo di prodotto

In base al tipo di prodotto, il respiratore Il mercato degli inalatori è segmentato in nebulizzatori, inalatori dosati e inalatori a polvere secca. Il segmento degli inalatori a polvere secca è ulteriormente biforcato in inalatori a polvere secca multidose e inalatori a polvere secca monodose. Il segmento degli inalatori a dose misurata (MDI) è ulteriormente suddiviso in inalatori a dose misurata a pressione e inalatori a dose misurata collegati. Il segmento dei nebulizzatori è suddiviso in nebulizzatori ad aria compressa, nebulizzatori ad aria a rete e nebulizzatori ad aria ad ultrasuoni. Nel 2022, il segmento degli inalatori a polvere secca rappresentava la quota di mercato maggiore. Tuttavia, si prevede che il segmento degli inalatori predosati (MDI) registrerà il CAGR più elevato durante il periodo di previsione.

Mercato degli inalatori respiratori, per tipo di prodotto: 2022 e 2028

Approfondimenti basati sulla tecnologia

Sulla base della tecnologia, il mercato degli inalatori respiratori è diviso in inalatori manuali e inalatori digitali. Il segmento degli inalatori manuali deteneva una quota di mercato maggiore nel 2022 e si prevede che registrerà un CAGR più elevato durante il periodo di previsione.

Approfondimenti basati sull'indicazione della malattia

In base all'indicazione della malattia, il Il mercato globale degli inalatori respiratori è segmentato in asma, BPCO, ipertensione arteriosa polmonare e altri. Il segmento dell’asma ha detenuto la quota maggiore del mercato nel 2022 e si prevede che crescerà al CAGR più elevato durante il periodo di previsione.   

Le strategie inorganiche e organiche come fusioni e acquisizioni sono ampiamente adottate dalle aziende nel mercato degli inalatori respiratori. Di seguito sono elencati alcuni recenti sviluppi chiave del mercato:

  • Nel settembre 2022, Beximco Pharmaceuticals ha lanciato ONRIVA TRIO BEXICAP, una capsula per inalatore secco. ONRIVA TRIO BEXICAP è la preparazione di Indacaterolo (150 µg), Glicopirronio (50 µg) e Mometasone (160 µg). Funziona in 3 modi per controllare i sintomi dell'asma. L'indacaterolo e il glicopirronio aiutano i muscoli delle vie aeree polmonari a rimanere rilassati per prevenire la broncocostrizione, mentre il mometasone aiuta a ridurre l'infiammazione. ONRIVA TRIO BEXICAP è indicato come terapia di mantenimento nell'asma persistente grave.
  • Nel giugno 2021, Cipla ha annunciato di aver ricevuto l'approvazione finale per la sua domanda di approvazione abbreviata di nuovo farmaco (ANDA) per la soluzione per inalazione di arformoterolo tartrato 15 mcg/2 ml dalla Food and Drug Administration statunitense. La soluzione per inalazione di tartrato di arformoterolo 15 mcg/2 mL di Cipla è una versione terapeutica generica equivalente classificata AN di Brovana di Sunovion Pharmaceuticals Inc.
  • Nel febbraio 2022, AstraZeneca e Honeywell hanno annunciato i loro piani di collaborazione per lo sviluppo di inalatori respiratori di nuova generazione che utilizzano il propellente HFO-1234ze, che ha fino al 99,9% in meno di potenziale di riscaldamento globale (GWP) rispetto ai propellenti attualmente utilizzati nei medicinali respiratori.
  • Nel gennaio 2023, la FDA ha approvato Airsupra [pressurizzato inalatore predosato (pMDI)] negli Stati Uniti per il trattamento al bisogno o la prevenzione della broncocostrizione. Airsupra è un inalatore predosato pressurizzato (pMDI) di prima classe, una combinazione di farmaci di salvataggio a dose fissa contenente albuterolo, un beta2-agonista a breve durata d'azione (SABA) e budesonide, un corticosteroide inalatorio antinfiammatorio (ICS). negli Stati Uniti.  

Profili aziendali

  • AstraZeneca Plc
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • GSK Plc
  • Koninklijke Philips NV
  • OMRON Corp
  • PARI Apparecchiature respiratorie, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • OPKO Health, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is meant by the respiratory inhalers market?

Respiratory inhalers are used to inhale drugs that are an essential part of treating chronic lung diseases. They are used both to prevent and treat exacerbations of these chronic diseases. They offer the advantage of avoiding systemic drug exposure while ensuring the drugs reach the lungs directly. Numerous products deliver drugs directly into the airways, such as dry powder inhalers, metered dose inhalers (MDIs), nebulizers and soft mist inhalers. The respiratory inhaler market is expected to flourish due to the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others.

What are the driving factors for the respiratory inhalers market across the globe?

Key factors driving the market growth are rising cases of respiratory disorders and growing adoption of generic inhalers.

Which segment led the respiratory inhalers market?

The respiratory inhalers market, by product type, is segmented into nebulizers, metered dose inhalers, and dry powder inhalers. The dry powder inhalers segment held the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period (2022–2028).

Which technology segment held the largest revenue (US$ Mn) in the respiratory inhalers market?

Based on technology, the global respiratory inhalers market is divided into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.

Who are the key players in the respiratory inhalers market?

Companies operating in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH, Cipla Ltd.;GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc.; Teva Pharmaceutical Industries Ltd.; and OPKO Health, Inc..

What is the regional market scenario of the respiratory inhalers market?

Global respiratory inhalers market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is likely to continue its dominance in the respiratory inhalers market during 2022–2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period.

The List of Companies - Respiratory Inhalers Market

  1. AstraZeneca Plc
  2. Beximco Pharmaceuticals Ltd.
  3. Boehringer Ingelheim International GmbH
  4. Cipla Ltd.
  5. GSK Plc
  6. Koninklijke Philips NV
  7. OMRON Corp
  8. PARI Respiratory Equipment, Inc.
  9. Teva Pharmaceutical Industries Ltd.
  10. OPKO Health, Inc.  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports